Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Executive Summary

Only 8% of original ANDAs submitted in the user fee program’s third year were approved on the first cycle, compared with 72% that received a complete response letter.

Advertisement

Related Content

Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Biosimilars: 40% First-Cycle Approval Rate Leaves Room For Improvement
Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending
Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development
ANDA Approval Times Get Optimistic Estimate In Budget Request
Generic Priority Review Expanded In Senate User Fee Bill
ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
US FDA Might Face Funding Penalty For Missing User Fee Goals
Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Topics

Advertisement
UsernamePublicRestriction

Register

PS119392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel